Moving Arts Leadership Forward: A Changing Landscape

Since 2009, the William and Flora Hewlett Foundation's Performing Arts Program has been making grants to help emerging arts leaders develop satisfying and successful careers through the Next Generation Arts Leadership Initiative. The first phase of that work, which ended in 2015, was funded in partnership with the James Irvine Foundation. It focused on training and retaining emerging arts leaders -- defined as eighteen to thirty-five-year-olds with ten years or less of arts experience -- in anticipation of a widely predicted wave of retirements. The Initiative made grants totaling $1.9 million to five leadership networks across California, and to statewide regranting programs, managed by the Center for Cultural Innovation to support professional development for individuals and innovative organizational practices. While an assessment conducted in 2011 showed that the Initiative was successful in achieving its early goals of building infrastructure and opportunities for younger arts leaders, the Performing Arts Program and our partners continued to grapple with a few persistent questions: what were we preparing up-and-coming leaders to do? To what degree did we aim to sustain the field as it exists or spur its transformation? Were we adequately preparing leaders for the challenges to come? To help answer these questions, in late 2014 we commissioned Michael Courville of Open Mind Consulting to reassess the arts leadership landscape in California and explore opportunities for future investments in arts leadership.The research was conducted in collaboration with a cross-section of local, regional, and national arts leaders, and with the Initiative's partners. It reveals that the arts landscape is in a state of flux and that there is a timely opportunity to reimagine how the nonprofit arts field defines and practices leadership

Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators

Recurrent Pseudomonas aeruginosa infections coupled with robust, damaging neutrophilic inflammation characterize the chronic lung disease cystic fibrosis (CF). The proresolving lipid mediator, 15-epi lipoxin A4 (15-epi LXA4), plays a critical role in limiting neutrophil activation and tissue inflammation, thus promoting the return to tissue homeostasis. Here, we show that a secreted P. aeruginosa epoxide hydrolase, cystic fibrosis transmembrane conductance regulator inhibitory factor (Cif), can disrupt 15-epi LXA4 transcellular biosynthesis and function. In the airway, 15-epi LXA4 production is stimulated by the epithelial-derived eicosanoid 14,15-epoxyeicosatrienoic acid (14,15-EET). Cif sabotages the production of 15-epi LXA4 by rapidly hydrolyzing 14,15-EET into its cognate diol, eliminating a proresolving signal that potently suppresses IL-8-driven neutrophil transepithelial migration in vitro. Retrospective analyses of samples from patients with CF supported the translational relevance of these preclinical findings. Elevated levels of Cif in bronchoalveolar lavage fluid were correlated with lower levels of 15-epi LXA4, increased IL-8 concentrations, and impaired lung function. Together, these findings provide structural, biochemical, and immunological evidence that the bacterial epoxide hydrolase Cif disrupts resolution pathways during bacterial lung infections. The data also suggest that Cif contributes to sustained pulmonary inflammation and associated loss of lung function in patients with CF

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes